Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.
FDA chooses not to approve new nasal spray for heart rhythm issues
Etripamil's journey toward FDA approval hit a roadblock. The agency requested additional information on the drug, including a new facility inspection, in a response letter sent to Milestone Pharmaceuticals.

Regulatory Roundup: Updates on Medtronic and LivaNova recalls, FDA-cleared AI models, a new heart valve and more

Read our recap of some of the biggest FDA-related stories that impacted cardiology in the last month.

healthcare value value-based care money dollar

FDA approves world’s most expensive drug, a hemophilia B treatment expected to cost $3.5M

The single-dose gene therapy can help patients reduce their risk of bleeding events and discontinue factor IX prophylaxis therapy.

ADHD medications and CVD: Lessons learned from a new meta-analysis of nearly 4 million patients

The new study, published in JAMA Network Open, should help ease any concerns patients may have about regularly taking ADHD medications.

Early catheter ablation superior to medication when treating ventricular tachycardia storm

VT storm is associated with a heightened risk of death or significant complications. Early catheter ablation, it seems, is the most effective treatment option for this potentially fatal condition.

OAC use among older AFib patients is on the rise

However, researchers noted, there is still considerable room for improvement.

FDA warns 7 companies for illegally selling dietary supplements that claim to treat CVD

The companies were given 15 days to provide an adequate response to the FDA's warning. The agency said its next step could include legal action.

Tracking the health benefits of influenza vaccines: ‘If you have heart failure, you should get your flu shot’

The new analysis focused on data from more than 5,000 heart failure patients throughout Asia, the Middle East and Africa.

Elon Musk and Eli Lilly: How a fake tweet caused chaos and reignited the debate over insulin prices

Updated Twitter policies have helped online pranksters cause mischief in recent days, including one specific user who impersonated Eli Lilly and Company and posted that insulin was now free. Lilly's CEO has now commented on the fake tweet read 'round the world—and what it could mean for the company going forward.

Pharmaceutics

Key takeaways from ACC.25: Advances in cardiovascular science

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes

FDA chooses not to approve new nasal spray for heart rhythm issues